Friedrich Foerster1,2, Denise Bamberger3, Jonathan Schupp4, Martin Weilbächer4, Leonard Kaps1, Stephanie Strobl1, Lydia Radi3, Mustafa Diken5, Dennis Strand2, Andrea Tuettenberg4, Peter R Wich3, Detlef Schuppan1,6. 1. Institute of Translational Immunology & Research Center for Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg-University Mainz, Langenbeckstraße 1, 55131 Mainz, Germany. 2. Department of Medicine I, University Medical Center, Mainz, Germany. 3. Institute of Pharmacy & Biochemistry, Johannes Gutenberg-University Mainz, Staudingerweg 5, Mainz, Germany. 4. Department of Dermatology, University Medical Center, Mainz, Germany. 5. TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz gGmbH, Freiligrathstraße 12, 55131 Mainz, Germany. 6. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Abstract
AIM: Evaluation of dextran-based nanoparticles (DNP) as a drug delivery system to target myeloid cells of the liver. MATERIALS & METHODS: DNP were synthesized and optionally PEGylated. Their toxicity and cellular uptake were studied in vitro. Empty and siRNA-carrying DNP were tested in vivo with regard to biodistribution and cellular uptake. RESULTS: In vitro, DNP were taken up by cells of the myeloid lineage without compromising their viability. In vivo, empty and siRNA-carrying DNP distributed to the liver where a single treatment addressed approximately 70% of macrophages and dendritic cells. Serum parameters indicated no in vivo toxicity. CONCLUSION: DNP are multifunctional liver-specific drug carriers which lack toxic side effects and may be utilized in clinical applications targeting liver macrophages.
AIM: Evaluation of dextran-based nanoparticles (DNP) as a drug delivery system to target myeloid cells of the liver. MATERIALS & METHODS:DNP were synthesized and optionally PEGylated. Their toxicity and cellular uptake were studied in vitro. Empty and siRNA-carrying DNP were tested in vivo with regard to biodistribution and cellular uptake. RESULTS: In vitro, DNP were taken up by cells of the myeloid lineage without compromising their viability. In vivo, empty and siRNA-carrying DNP distributed to the liver where a single treatment addressed approximately 70% of macrophages and dendritic cells. Serum parameters indicated no in vivo toxicity. CONCLUSION:DNP are multifunctional liver-specific drug carriers which lack toxic side effects and may be utilized in clinical applications targeting liver macrophages.
Authors: Jacob W Shreffler; Jessica E Pullan; Kaitlin M Dailey; Sanku Mallik; Amanda E Brooks Journal: Int J Mol Sci Date: 2019-11-30 Impact factor: 5.923
Authors: Jonathan David Hinchliffe; Alakananda Parassini Madappura; Syed Mohammad Daniel Syed Mohamed; Ipsita Roy Journal: Polymers (Basel) Date: 2021-03-29 Impact factor: 4.329